Zhejiang Tianyuan Bio-Pharmaceutical Co., Ltd.  
Home Contact us sitemap
  News releases
Meningococcal Vaccine Facility Passed GMP Inspection
Publisheradmin Date:2008-1-14 Font: Big Medium Small

In January 2008 Tianyuan's new bacterial vaccine facility for the manufacture of Meningococcal Polysaccharide AC and ACYW135 vaccine successfully passed the GMP inspection performed by the Chinese SFDA.
Tianyuan is now officially allowed to manufacture and sell vaccines against Meningococcal Polysaccharide AC and ACYW135 in China.
Tianyuan achieved an important milestone, being the first company on the Chinese market offering its highly pure and effective Meningococcal vaccines.
Group AC Meningococcal Polysaccharide Vaccine furthermore reaps the benefits of a two-year patent protection period in China while Group ACYW135 Meningococcal Polysaccharide Vaccine enjoys a three-year patent protection period.
Tianyuan now aspires to get the WHO-prequalification for its vaccines.
The bacterial vaccine facility was designed by famous Chinese design institutes and the installation was carried out by KCS from the Netherlands and Suzhou Suntec Clean Room Installation Co., Ltd. Currently Tianyuan is in the last steps of qualification for its Diphteria, acellular Pertussis and Typhoid facility as well as for its Tetanus facility.

About Meningococcal Polysaccharide Vaccine

Meningococcal meningitis caused by the bacterium Neisseria meningitides, is a serious infection of the fluid in the spinal cord and the fluid that surrounds the brain and can result in brain damage and even death.
The bacteria are spread by direct close contact with the discharges from the nose or throat of an infected person.
Meningococcal meningitis is most common in infants and children. People who have had close or prolonged contact with a patient with meningococcal meningitis are at increased risk.

Bacterial meningitis can be treated with antibiotics, but an early diagnosis and treatment is crucial.
To prevent the disease, vaccines are the best choice.

Tianyuan's Meningococcal Polysaccharide Vaccine YUNAONING will become available as divalent (AC) or quadrivalent (ACYW135) formulation by mid of 2008. The vaccines consists of highly purified polysaccharides of the different meningococcal serogroups.
Although mostly serogroups A and C are prevalent in China, the quadrivalent vaccine provides additional protection. Both vaccines are high-quality vaccines. Tianyuan aspires to get the WHO-prequalification for its vaccines.

Print || Close Windows
Copyright(C)2008,Zhejiang Tianyuan Bio-Pharmaceutical Co., Ltd. All Rights Reserved.
 Supported by  ChinaPharmNet Toocle